Jul 07

BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor – peptide-HLA interactions

T cell therapies open up promising therapeutic perspectives and are currently still limited to only a few specific areas of application. In the field of oncology, two therapeutics have already been successfully launched on the market.

In order to make this innovative form of therapy more rapidly available on a broad scale, BioCopy has further developed its innovative technology platform and will in future be able to investigate T cell receptors in a high-throughput process. Based on the positive interim results, BioCopy can announce a promising collaboration with Immatics and this already one year after the start of operations at its new company location in Emmendingen / Germany.

Read Press Release